- Net Sales & Core EBIT Growth Net sales rose 2.9% to CHF 11.1 billion; core EBIT increased 6.7% to CHF 349 million at constant exchange rates.
- M&A & Strategic Partnerships Executed 9 acquisitions and expanded partnerships with Bayer, Eli Lilly, Nestle, and Thermo Fisher to boost client portfolio.
- Segment Performance Healthcare led with 4.6% net sales growth (CHF 5.8 billion) and 8.1% core EBIT growth in H2; Performance Materials improved core EBIT margin to 8.2%.
- Financial Resilience Generated CHF 215.5 million free cash flow (95.2% cash conversion) and reduced gross debt by CHF 50 million, improving equity ratio to 33.1%.
- 5-Year Growth Trends Net sales CAGR of 4.2% and core EBIT CAGR of 11.6% over five years, with core EBIT margin expanding by 60 bps.
Business Unit Performance
The company's business units performed well, with Healthcare net sales growing by 4.6% to CHF 5.8 billion, and Core EBIT increasing by 8.1% in the second half of the year. Consumer Goods achieved net sales growth of 1.2%, with a marked acceleration of 2.8% in the second half. Performance Materials' net sales grew by 1.4%, and Core EBIT increased by 1.9%, with the core EBIT margin improving to 8.2%. As Stefan Butz noted, "Q3 saw a bounce back with strong results, followed by a normalization in Q4," indicating a recovery in the Performance Materials segment.
Valuation and Outlook
DKSH's current valuation metrics indicate a P/E Ratio of 21.36, a P/B Ratio of 2.53, and a Dividend Yield of 3.67%. The company's return on equity (ROE) is 11.26%, and its return on invested capital (ROIC) is 9.22%. Analysts estimate next year's revenue growth at 3.7%. With its resilient performance, diversified business segments, and strong cash flow generation, DKSH is well-positioned for future growth.
Segmental Trends and Opportunities
In the consumer goods segment, DKSH has seen a trend change driven by its strategy pivot to focus on higher premium categories and more profitable clients, resulting in margin expansion from 1.7% in 2019 to 2.7% in 2025. The company is also exploring opportunities in AI to further accelerate top-line growth. In the healthcare business, DKSH has seen a 10 bps increase in margin over the last 5 years, driven by a higher focus on high-margin business and commercial outsourcing.
Risk Management and Inventory Levels
DKSH's inventory levels remain elevated, with group stock turns at 7x to 8x. However, the company is monitoring these closely and adjusting its inventory levels accordingly. The company's currency risk is primarily translational, and it hedges all transactions in non-U.S. dollars. With its lean working capital and efficient capital allocation, DKSH is well-positioned to navigate potential risks and challenges.